(Q36557868)

14 August 2017

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort (English)

1 reference

multicenter clinical trial

14 August 2017

0 references

author

Ashwin N Ananthakrishnan

17

object named as

Ashwin Ananthakrishnan

1 reference

14 August 2017

Edward Shelton

1

1 reference

14 August 2017

Jessica R Allegretti

2

1 reference

14 August 2017

Betsy Stevens

3

1 reference

14 August 2017

Matthew Lucci

4

1 reference

14 August 2017

Hamed Khalili

5

1 reference

14 August 2017

Deanna D Nguyen

6

1 reference

14 August 2017

Jenny Sauk

7

1 reference

14 August 2017

Cosmas Giallourakis

8

1 reference

14 August 2017

John Garber

9

1 reference

14 August 2017

Matthew J Hamilton

10

1 reference

14 August 2017

Michal Tomczak

11

1 reference

14 August 2017

Fredrick Makrauer

12

1 reference

14 August 2017

Robert B Burakoff

13

1 reference

14 August 2017

Jonathan Levine

14

1 reference

14 August 2017

Punyaganie de Silva

15

1 reference

14 August 2017

Sonia Friedman

16

1 reference

14 August 2017

Joshua R Korzenik

18

1 reference

14 August 2017

Vijay Yajnik

19

1 reference

14 August 2017

17 August 2015

1 reference

Inflammatory Bowel Diseases

14 August 2017

1 reference

14 August 2017

21

1 reference

14 August 2017

2879-2885

1 reference

14 August 2017

12

1 reference

Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Introducing vedolizumab to clinical practice: who, when, and how?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Vedolizumab as induction and maintenance therapy for Crohn's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Vedolizumab as induction and maintenance therapy for ulcerative colitis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

New and emerging treatments for ulcerative colitis: a focus on vedolizumab

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

A simple clinical colitis activity index

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

A simple index of Crohn's-disease activity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Inhibition of leukocyte trafficking in inflammatory bowel disease.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4745906

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

21 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1097%2FMIB.0000000000000561

Long-term outcome after infliximab for refractory ulcerative colitis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1097%2FMIB.0000000000000561

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

21 January 2018

1 reference

12 December 2020

Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population

1 reference

12 December 2020

Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis

1 reference

12 December 2020

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis

1 reference

12 December 2020

Natalizumab and PML: a risky business?

1 reference

12 December 2020

Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome

1 reference

12 December 2020

Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease

1 reference

12 December 2020

10.1097/MIB.0000000000000561

Identifiers

DOI

1 reference

14 August 2017

1 reference

14 August 2017

1 reference